Nature Search

Author Correction: Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial

Shu-Qiang Yuan
Run-Cong Nie
Feng Wang
Amendments and Corrections08 Jan 2024
Nature Medicine

Volume: 30, P: 605
Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial

In the phase 2 trial NEOSUMMIT-01, perioperative treatment of patients with locally advanced gastric or gastro-esophageal junction adenocarcinoma with anti-PD-1 and SOX/XELOX versus SOX/XELOX alone improved pathological complete response or near-complete response rate.

Shu-Qiang Yuan
Run-Cong Nie
Feng Wang
Research02 Jan 2024
Nature Medicine

Volume: 30, P: 552-559
CLPTM1L interacts with ERLIN2 to stabilize SREBP1 and drive tumorigenesis in nasopharyngeal carcinoma

Jian Zhang
Shu-Qiang Liu
Qian Cui
ResearchOpen Access23 Jun 2025
Cell Death & Disease

Volume: 16, P: 1-10
Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial

Run-Cong Nie
Shu-Qiang Yuan
Ying-Bo Chen
ResearchOpen Access05 Feb 2025
Signal Transduction and Targeted Therapy

Volume: 10, P: 1-9
Epstein-Barr virus hijacks histone demethylase machinery to drive epithelial malignancy progression through KDM5B upregulation

Ya-Qing Zhou
Jia-Xin Jiang
Jin-Xin Bei
ResearchOpen Access10 Mar 2025
Signal Transduction and Targeted Therapy

Volume: 10, P: 1-16

Quick links

Search

Filter By:

Author Correction: Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial

Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial

CLPTM1L interacts with ERLIN2 to stabilize SREBP1 and drive tumorigenesis in nasopharyngeal carcinoma

Perioperative tislelizumab plus chemotherapy for locally advanced gastroesophageal junction adenocarcinoma (NEOSUMMIT-03): a prospective, nonrandomized, open-label, phase 2 trial

Epstein-Barr virus hijacks histone demethylase machinery to drive epithelial malignancy progression through KDM5B upregulation

Search

Quick links